



This open access document is posted as a preprint in the Beilstein Archives at <https://doi.org/10.3762/bxiv.2023.20.v1> and is considered to be an early communication for feedback before peer review. Before citing this document, please check if a final, peer-reviewed version has been published.

This document is not formatted, has not undergone copyediting or typesetting, and may contain errors, unsubstantiated scientific claims or preliminary data.

Preprint Title Metal catalyst-free *N*-Allylation/alkylation of Imidazole and Benzimidazole with Morita-Baylis-Hillman (MBH) alcohols and acetates

Authors Olfa Mhasni, Jalloul Bouajila and Farhat Rezgui

Publication Date 23 Mai 2023

Article Type Full Research Paper

Supporting Information File 1 Supporting Information.docx; 6.9 MB

ORCID® iDs Olfa Mhasni - <https://orcid.org/0009-0002-9931-0895>; Farhat Rezgui - <https://orcid.org/0000-0002-9616-0716>



License and Terms: This document is copyright 2023 the Author(s); licensee Beilstein-Institut.

This is an open access work under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>). Please note that the reuse, redistribution and reproduction in particular requires that the author(s) and source are credited and that individual graphics may be subject to special legal provisions.

The license is subject to the Beilstein Archives terms and conditions: <https://www.beilstein-archives.org/xiv/terms>.

The definitive version of this work can be found at <https://doi.org/10.3762/bxiv.2023.20.v1>

1 **Metal catalyst-free *N*-Allylation/alkylation of Imidazole and Benzimidazole**
2 **with Morita–Baylis–Hillman (MBH) alcohols and acetates**


3
4 **Olfa MHASNI^{a,*}, Jalloul BOUAJILA^b, Farhat REZGUI^c**
5

6 ^a *Laboratory of Materials, Treatment and Analysis LMTA, LR 15 INRAP 03, National Institute*
7 *of Research and Physico-Chemical Analysis (INRAP), Biotechpôle Sidi Thabet 2020, Tunisia*
8 *E-mail : olfa.mha@gmail.com*

9 ^b *Paul Sabatier University, Toulouse 3, Laboratoire de Génie Chimique UMR 5503 Toulouse*
10 *France. E-mail : jalloul.bouajila@univ-tlse3.fr*

11 ^c *University of Tunis El Manar, Laboratory of Organic Chemistry, Faculty of Sciences, Campus,*
12 *2092 Tunis, Tunisia. E-mail : farhat.rezgui@fst.utm.tn*

13
14 **ABSTRACT:** A highly α -regioselective *N*-nucleophilic allylic substitutions of
15 cyclic MBH alcohols and acetates with imidazole or benzimidazole, in toluene at
16 reflux with an azeotropic distillation, was successfully carried out with no catalysts
17 or additives, affording the corresponding *N*-substituted imidazole derivatives in
18 good yields. On the other hand, in refluxing toluene or methanol, the aza-Michael
19 additions of imidazole onto acyclic MBH alcohols was performed using DABCO
20 as an additive, leading to the corresponding 1,4-adducts in 70-84% yields.




21
22
23 **Keywords:** Morita–Baylis–Hillman; imidazole; allylic substitution; aza-Michael
24 addition.

25 **INTRODUCTION**

26 Morita–Baylis–Hillman (MBH) adducts are multi-functionalized compounds
27 having both hydroxyl moiety and Michael acceptor unit. They have been found as
28 valuable synthons and useful precursors for the synthesis of various biologically
29 active molecules.¹ Recently, MBH adducts, as electrophilic substrates, have been

30 employed to achieve fruitful results in allylic substitution reactions with various
31 nucleophiles, including C- and heteronucleophiles, such as compounds bearing
32 –OH, –SH and –NH groups.² Among them, the carbon–nitrogen bond formation
33 through N-nucleophilic substitutions plays a very useful role for the synthesis of
34 numerous compounds exhibiting various biological activities.^{1,2}
35 In this context, imidazole moiety is widely known as one of the most group which
36 plays efficient roles in bioactive compounds.³ For instance, a number of
37 N-substituted imidazole derivatives, such as miconazole, ketoconazole,
38 genaconazole, and bifonazole have become well-established drugs for the treatment
39 of numerous mycotic infections (Figure 1).⁴ Therefore, the development of new
40 methods for the preparation of such compounds is highly required.




41
42 **Figure 1.** Medicines containing imidazole nucleus

43 The MBH acetates, instead of the corresponding alcohols, have been extensively
44 used as precursors in the nucleophilic allylic substitutions with amines, presumably
45 due to the perceived poor leaving group ability and low reactivity of the hydroxyl
46 moiety. Interestingly, the direct nucleophilic substitutions of the corresponding
47 alcohols have drawn much attention because of the availability of these substrates
48 and the formation of water as the sole non-toxic by-product in the reaction.⁵ In
49 general, the previous methods for the amination of MBH alcohols needed catalysts
50 or additives such as FeCl₃,⁶ In(OTf)₃,⁷ MoCl₅,⁸ AuCl₃,⁹ and I₂¹⁰ as Lewis acids.

51 Alternatively, Yang et al.¹¹ have developed a catalytic system involving
 52 Pd/Ti(OⁱPr)₄ or Pd/carboxylic acid for the direct allylation of anilines with alcohols.


53 The synthesis of *N*-allylation imidazole derivatives **3** has been previously
 54 carried out using acyclic MBH adducts bearing good leaving groups such as
 55 bromide derivatives in Et₃N-THF,¹² (Scheme 1, eq.1 (i)) and acetates in THF-
 56 water,¹³ (Scheme 1, eq.1 (ii)), or MBH alcohols in the presence of CDI (i.e., 1,1'-
 57 carbonyl diimidazole) in acetonitrile (Scheme 1, eq.1, (iii)).¹⁴ In the last case, as the
 58 hydroxyl moiety is not a good leaving group, such alcohols were *in situ* converted
 59 into the corresponding *O*-allyl carbamates as leaving groups, followed by their
 60 reaction with imidazoles, affording the S_N2' products **3** (Scheme 1, eq. 1, iii)).

Previous work:



Reagents and conditions: (i) LG = Br, EWG = CO₂Me; Et₃N, THF. (ii) LG = OAc, EWG = CO₂Me, CO₂Et; THF-H₂O.
 (iii) LG = OH, EWG = CO₂R, CN; CDI, CH₃CN.

This work:



61
 62

63 **Scheme 1.** Synthesis of *N*-substituted imidazole derivatives from MBH adducts

64 Correlatively, we have previously reported a direct amination of cyclic MBH
 65 alcohols **4** with morpholine in the presence of imidazole **2a**, as a powerful
 66 nucleophilic additive, affording, *via* competitive allylic nucleophilic substitutions in
 67 toluene at reflux, a mixture of the corresponding *N*-substituted morpholine and *N*-
 68 substituted imidazole derivatives **6**.¹⁵ In addition, the literature survey showed that
 69 nucleophilic allylic substitutions of acyclic/cyclic MBH adducts **1,4,5**, bearing
 70 good or poor leaving groups, using imidazole derivatives, as nucleophilic reagents,

71 has not been extensively developed. Therefore, in continuation of our previous
72 study on nucleophilic allylic substitutions of MBH adducts,¹⁵⁻¹⁸ we disclose in this
73 work a simple efficient procedure for the synthesis of *N*-substituted imidazoles
74 **6-8**, either through direct conversions of the corresponding cyclic MBH alcohols **4**
75 as well as acetates **5**, in the presence of imidazoles **2a,b**, as nucleophilic reagents,
76 without catalysts or activating agents (Scheme 1, equation 2), or from acyclic
77 MBH alcohols **1**, using DABCO, as a powerful nucleophilic additive (Scheme 1,
78 equation 3).

79 ■ RESULTS AND DISCUSSION

80 In our first investigations, we selected the reaction of the primary acetate **5a**, as the
81 model substrate bearing a good leaving group, with imidazole **2a** (2 equiv), as a
82 powerful nucleophilic reagent. The reaction was achieved with no need of a
83 catalyst or any additive, in toluene at reflux, affording within 24 h the S_N2-*type*
84 product **6a** in 82% yield (Table 1, entry 1). Similarly, the five-membered acetate **5b**
85 reacted, under the same conditions, and gave the *N*-allylic imidazole **6b** in 65%
86 yield (Table 1, entry 2).

87 Furthermore, treatment of secondary acetates **5c,d** with imidazoles **2a,b** (2 equiv) in
88 refluxing toluene, afforded the *N*-substituted imidazoles **6c,d** and **7a** within ca. 24 h
89 in 69-87% yields (Table 1, entries 3-5).

90

91


92

93

94







95

96 **Table 1.** Allylation of imidazole derivatives **2a,b** with cyclic MBH adducts **4,5**



97
98

| Entry | MBH adduct 4 or 5 | Imidazole 2a or 2b | Time (h) | Product 6 or 7 | Yield (%) 6 or 7 |
|-------|------------------------------------|-------------------------------------|-------------|---------------------------------|--------------------------------------|
| 1 | 5a | 2a | 24 | 6a | 82 |
| 2 | 5b | 2a | 24 | 6b | 65 |
| 3 | 5c | 2a | 24 | 6c | 75 |
| 4 | 5c | 2b | 48 | 7a | 87 |
| 5 | 5d | 2a | 24 | 6d | 69 |
| 6 | 4a | 2a | 48 | 6a | 88 |

| | | | | | |
|----|---|-----------|----|-----------|----|
| 7 |  | 2a | 24 | 6b | 55 |
| 8 |  | 2b | 72 | 7b | 80 |
| 9 |  | 2b | 72 | 7c | 72 |
| 10 |  | 2a | 48 | 6c | 76 |
| 11 |  | 2a | 24 | 6d | 60 |
| 12 |  | 2b | 72 | 7d | 85 |


99

100 Having established the optimized conditions for the amination of primary and
 101 secondary acetates **5a-d** (Table 1, entries 1-5), carrying a good leaving group
 102 (OAc), we turned our attention to the investigation of the direct amination of MBH
 103 alcohols **4a-d**, with a poor leaving group (OH). Under the previous conditions (2
 104 equiv of imidazole, toluene, reflux), the conversion of alcohol **4a** into the
 105 corresponding imidazole **6a** was very slow and the starting materials were almost
 106 recovered. However, the continuous removal of water, obtained from the direct
 107 amination of alcohol **4a**, by azeotropic distillation, shifts the position of equilibrium
 108 in the direction of the formation of the allylation imidazole **6a** in 88% good yield
 109 (Table 1, entry 6).

110 This protocol was also successfully extended to the reaction of the primary five-
111 membered alcohol **4b** with imidazole **2a** as well as to that of alcohols **4a,b** with
112 benzimidazole **2b**, leading to the S_N2-type products **6b** and **7b,c**, respectively, in
113 55-80% yields (Table 1, entries 7-9).

114 In addition, we have shown that the direct amination of secondary alcohols **4c-d**
115 could be achieved with imidazole derivatives **2a,b**, under the conditions established
116 above, affording, within 24-72h, the allylation products **6c,d** and **7d** in 60-85%
117 yields (Table 1, entries 10-12).

118 Mechanistically, we believe that the nucleophilic allylic substitutions of
119 alcohols **4**, such as **4a**, starts with a conjugate addition of imidazole **2a** at the C_β
120 position of the Michael acceptor **4a**, followed by elimination of the hydroxyl
121 moiety, affording the intermediate **I**. Similarly, a further second β'-conjugate
122 addition of imidazole **2a** to **I** might occur, followed by elimination of imidazole
123 **2a**, providing finally the allylic derivative **6a** (Scheme 2).^{16,19} It is notable that such
124 reaction mechanism, involving the intermediate **I**, was previously explored by
125 Smith²⁰ and supported by Tamura studies.²¹




127 **Scheme 2.** Proposed mechanism for the allylation of imidazole with alcohol **4a**

128 Next, in order to explore the scope of the above process, we have also investigated
129 the direct allylation of imidazole **2a** with acyclic MBH alcohol **1**. In our first
130 experiment, this substrate did not react with imidazole **2a** in toluene at reflux, within
131 24 h, with or without azeotropic distillation, and the starting materials were
132 completely recovered (Table 2, entry 1). Moreover, the addition of additives to the
133 previous reaction mixture, such as DMAP¹⁶⁻¹⁹ or molecular sieves 4 Å, commonly
134 used to mediate nucleophilic allylic substitutions, did not lead to a notable
135 improvement of the reaction outcome (Table 2, entries 2,3). However the use of
136 DABCO, commonly used as a powerful catalyst or a nucleophilic additive in the

137 reaction of acyclic MBH adducts with various nucleophiles,^{13,22-25} did not afford the
 138 S_N2/S_N2' products but provided the 1,4-adduct **8** in 84% yield (Table 2, entry 4).
 139 Alternatively, we also investigated the reaction of alcohol **1** and imidazole **2a**
 140 (2 equiv), without any catalyst or additive, in refluxing methanol, commonly
 141 employed as solvent in the conversion MBH adducts using a variety of amines.²⁶
 142 Our study showed that the imidazole **2a** reacted with alcohol **1**, without any
 143 additive or in the presence of DABCO, as additive, in a 1,4-fashion, leading to the
 144 imidazole derivative **8**, within 10 h, in 65-68 % yields (Table 2, entries 5,6).

145 **Table 2.** Optimization of the reaction conditions of imidazole **2a** with acyclic
 146 MBH **1**.



147

| Entry | Additive (1 equiv) | Solvent | Time (h) | 8 (Yield %) |
|-------|-----------------------|---------|----------|--------------------|
| 1 | None | Toluene | 24 | n.r |
| 2 | MS 4Å | Toluene | 24 | n.r |
| 3 | DMAP | Toluene | 24 | 25 |
| 4 | DABCO | Toluene | 24 | 84 |
| 5 | None | MeOH | 10 | 65 |
| 6 | DABCO | MeOH | 10 | 68 |


148

149 Therefore, in our further experiments on imidazole-mediated the conversion of
 150 acyclic MBH alcohols, the toluene at reflux was retained as solvent of choice for
 151 the reaction using DABCO as additive.

152 Next, the treatment of acrylate-derived alcohols **1b,c** (**1b**, EWG=CO₂Et, R=Ph; **1c**,
 153 EWG = CO₂Me, R=Me), under the previously optimized conditions, afforded the
 154 corresponding 1,4-adducts **8b,c**, in 70-75% yields, (Table 3, entries 2,3), as 55:45
 155 and 59:41 mixtures of inseparable diastereomers, respectively. The relative
 156 diastereomeric ratios (dr) were determined by means of ¹H NMR based on the
 157 proton at the α position of the EWG moiety (Table 3).

158 In order to explore the scope of this synthetic approach, we have studied the
 159 reaction of ketone-derived alcohols such as **1d** (EWG=COPh, R=H), **1e**
 160 (EWG=COⁿPr, R=H), **1f** (EWG=COC-C₆H₁₁, R = H), and imidazole under the
 161 established reaction conditions, and we have observed that the conversion was
 162 complete but wasn't clean. However in methanol at reflux, a clean reaction took
 163 place, providing the corresponding 1,4-adducts **8d-f** in 70-76% yields (Table 3,
 164 entries 4-6).

165 **Table 3.** Michael additions of imidazole **2a** onto acyclic MBH alcohols **1a-f**



R = H, Me, Ph
 EWG = CO₂Et, CO₂Me, COPh,
 COⁿPr, COC₆H₁₁

166

| Entry | Product | R | EWG | Solvent | Time (h) | 8 (Yield %), dr ^a |
|-------|-----------|----|----------------------------------|---------|----------|-------------------------------------|
| 1 | 8a | H | CO ₂ Et | Toluene | 24 | 84 None |
| 2 | 8b | Ph | CO ₂ Et | Toluene | 24 | 75 55:45 |
| 3 | 8c | Me | CO ₂ Me | Toluene | 24 | 70 59:41 |
| 4 | 8d | H | COPh | MeOH | 10 | 70 None |
| 5 | 8e | H | CO ⁿ Pr | MeOH | 12 | 76 None |
| 6 | 8f | H | COC ₆ H ₁₁ | MeOH | 12 | 73 None |

167 ^aDetermined from ¹H NMR of the crude reaction mixture.

168 ■ CONCLUSIONS

169 We have successfully developed an efficient *N*-nucleophilic allylic
 170 substitutions of cyclic MBH alcohols **4** and acetates **5** with imidazoles in refluxing
 171 toluene. The new *N*-substituted imidazoles **6,7** were afforded in high purity and
 172 good yields.

173 In toluene or methanol at reflux, acyclic MBH alcohols reacted with
174 imidazole in a 1,4-fashion, leading to the corresponding Michael adducts **8** in 70-
175 84% yields.

176 Synthetic applications of such imidazole derivatives,^{14,27} as well as their
177 biological evaluation²⁸ work underway in our laboratory.

178 ■ EXPERIMENTAL SECTION

179 IR spectra were recorded on a Bruker (IFS 66v/S) spectrometer. ¹H NMR and ¹³C
180 NMR spectra were recorded either on a Bruker AC-500 spectrometer (300 MHz for
181 ¹H and 125 MHz for ¹³C) in CDCl₃, using TMS as an internal standard (chemical
182 shifts in δ values, J in Hz). High resolution mass spectra (HRMS) were recorded as
183 EI-HRMS on an Autospec Ultima/micromass mass spectrometer. Gas
184 chromatography–mass spectrometry (GCMS) were recorded on an Agilent
185 Technologies 6890N. Analytical thin layer chromatography (TLC) was performed
186 using Fluka Kieselgel 60 F254 precoated silica gel plates. Visualization was
187 achieved by UV light (254 nm). Flash chromatography was performed using Merck
188 silica gel 60 and a gradient solvent system ether/acetone as eluant).

189 **Typical procedure for the α -substitution of cyclic MBH adducts with** 190 **imidazoles**

191 A mixture of allyl acetate **5a** (2 mmol, 0.33 g) or allyl alcohol **4a** (2 mmol, 0.25 g)
192 and imidazole **2a** (4 mmol, 0.27 g) in toluene (25 mL) was heated under reflux (for
193 **5a**) or in a Dean stark apparatus (for **4a**). After completion (TLC), the reaction
194 mixture was cooled, washed with brine and dried. The toluene was removed and
195 the residue was purified by column chromatography on silica gel (acetone/ether,
196 8:2) to give the pure *N*-substituted imidazole **6a**.

197 **2-((1H-imidazol-1-yl)methyl)cyclohex-2-enone 6a**

198 Yield: 82%; yellow oil; ν (CHCl₃) 2932, 1666, 1503, 1380, 1227, 1074 cm⁻¹; ¹H
199 NMR (CDCl₃, 500 MHz): δ_{H} 7.47 (s, 1H), 7.01 (s, 1H), 6.89 (s, 1H), 6.64 (t, J = 4.0
200 Hz, 1H), 4.70 (s, 2H), 2.47–2.35 (m, 4H), 2.04–1.98 (m, 2H); ¹³C NMR (CDCl₃,

201 125 MHz): δ_{C} 197.6, 147.7, 137.6, 135.2, 129.3, 119.4, 45.5, 37.9, 25.8, 22.6;
202 HRMS (EI): MH^+ , found 177.1022. $\text{C}_{10}\text{H}_{13}\text{N}_2\text{O}$ requires 177.1028.

203 **2-((1H-imidazol-1-yl)methyl)cyclopent-2-enone 6b**

204 Yield: 65%; yellow oil; ν (CHCl_3) 2924, 1693, 1504, 1388, 1227, 1073 cm^{-1} ; ^1H
205 NMR (CDCl_3 , 500 MHz): δ_{H} 7.51 (s, 1H), 7.34 (t, $J = 4.0$ Hz, 1H), 7.02 (s, 1H),
206 6.94 (s, 1H), 4.71 (s, 2H), 2.64–2.60 (m, 2H), 2.46–2.43 (m, 2H); ^{13}C NMR
207 (CDCl_3 , 125 MHz): δ_{C} 207.2, 160.2, 142.1, 137.4, 129.5, 119.3, 41.7, 34.6, 26.7;
208 HRMS (EI): MH^+ , found 163.0866. $\text{C}_9\text{H}_{11}\text{N}_2\text{O}$ requires 163.0871.

209 **2-((1H-imidazol-1-yl)ethyl)cyclohex-2-enone 6c**

210 Yield: 75%; yellow oil; ν (CHCl_3) 2935, 1665, 1497, 1381, 1226, 1077 cm^{-1} ; ^1H
211 NMR (CDCl_3 , 500 MHz): δ_{H} 7.55 (s, 1H), 7.03 (s, 1H), 6.93 (s, 1H), 6.57 (t, $J = 4.0$
212 Hz, 1H), 5.34 (q, $J = 6.2$ Hz, 1H), 2.47–2.36 (m, 4H), 2.02–1.96 (m, 2H), 1.62 (d, J
213 = 6.2 Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C} 197.3, 145.4, 140.4, 136.2, 128.9,
214 117.8, 50.4, 38.4, 25.7, 22.4, 19.8; MS (m/z): 191 (13), 190 (M^+ , 100), 189 (8),
215 175 (15), 162 (16), 149 (7), 134 (7), 123 (62), 107 (10), 95 (48), 81 (27), 79 (38),
216 69 (50), 67 (75), 55 (50); HRMS (EI): MH^+ , found 191.1188. $\text{C}_{11}\text{H}_{15}\text{N}_2\text{O}$ requires
217 191.1184.

218 **2-((1H-imidazol-1-yl)ethyl)cyclopent-2-enone 6d**

219 Yield: 69%; yellow oil; ν (CHCl_3) 2926, 1695, 1496, 1395, 1227, 1077 cm^{-1} ; ^1H
220 NMR (CDCl_3 , 500 MHz): δ_{H} 7.59 (s, 1H), 7.28 (t, $J = 4.0$ Hz, 1H), 7.03 (s, 1H),
221 7.01 (s, 1H), 5.11 (q, $J = 6.0$ Hz, 1H), 2.62–2.60 (m, 2H), 2.46–2.43 (m, 2H), 1.71
222 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C} 207.2, 159.1, 146.6, 136.0,
223 129.0, 117.8, 49.1, 35.2, 26.6, 19.5; MS (m/z): 177 (12), 176 (M^+ , 100), 175 (7),
224 161 (1), 147 (9), 109 (43), 81 (54), 79 (74), 69 (33), 67 (13), 53 (31); HRMS (EI):
225 MH^+ , found 177.1031. $\text{C}_{10}\text{H}_{13}\text{N}_2\text{O}$ requires 177.1028.

226 **2-((1H-benzimidazol-1-yl)ethyl)cyclohex-2-enone 7a**

227 Yield: 87%; yellow oil; ^1H NMR (CDCl_3 , 500 MHz): δ_{H} 8.03 (s, 1H), 7.73–7.71
228 (m, 1H), 7.21–7.15 (m, 3H), 6.49 (t, $J = 4.0$ Hz, 1H), 5.52 (q, $J = 6.0$ Hz, 1H),
229 2.38–2.34 (m, 2H), 2.25–2.19 (m, 2H), 1.89–1.83 (m, 2H), 1.70 (d, $J = 6.0$ Hz,

230 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C} 197.5, 146.0, 143.7, 141.3, 133.9, 133.2,
231 122.8, 122.1, 120.1, 110.4, 49.1, 38.1, 25.6, 22.3, 19.4 ; MS (m/z): 241 (17), 240
232 (M^+ , 100), 239 (10), 226 (15), 225 (100), 211 (10), 197 (7), 183 (5), 169 (5), 145
233 (14), 119 (15), 118 (55), 91 (8), 77 (7), 67 (9), 55 (5); HRMS (EI): MH^+ , found
234 241.1347. $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}$ requires 241.1341.

235 **2-((1H-benzimidazol-1-yl)methyl)cyclohex-2-enone 7b**

236 Yield: 80%; yellow oil; ^1H NMR (CDCl_3 , 500 MHz): δ_{H} 7.85 (s, 1H), 7.68–7.62
237 (m, 1H), 7.22–7.08 (m, 3H), 6.49 (t, $J = 4.0$ Hz, 1H), 4.78 (s, 2H), 2.30–2.25 (m,
238 2H), 2.15–2.10 (m, 2H), 1.82–1.74 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C}
239 197.7, 147.8, 143.6, 143.3, 133.8, 133.3, 122.6, 121.7, 119.9, 109.6, 43.2, 37.6,
240 25.3, 22.2; MS (m/z): 227 (16), 226 (M^+ , 100), 225 (33), 211 (5), 198 (28), 197
241 (19), 183 (7), 170 (30), 169 (24), 157 (7), 131 (22), 118 (15), 104 (4), 90 (5), 77
242 (7), 63 (3), 53 (6); HRMS (EI): MH^+ , found 227.1189. $\text{C}_{14}\text{H}_{15}\text{N}_2\text{O}$ requires
243 227.1184.

244 **2-((1H-benzimidazol-1-yl)methyl)cyclopent-2-enone 7c**

245 Yield: 72%; yellow oil; ^1H NMR (CDCl_3 , 500 MHz): δ_{H} 7.92 (s, 1H), 7.75–7.74
246 (m, 1H), 7.29–7.18 (m, 4H), 4.87 (s, 2H), 2.51–2.49 (m, 2H), 2.39–2.37 (m, 2H);
247 ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C} 207.6, 160.6, 143.6, 143.4, 140.9, 133.4, 123.1,
248 122.2, 120.3, 109.6, 39.7, 34.5, 26.7; MS (m/z): 213 (14), 212 (M^+ , 100), 211 (46),
249 197 (2), 184 (11), 183 (39), 169 (17), 156 (21), 131 (10), 118 (14), 104 (5), 90 (4),
250 77 (5), 63 (3), 53 (3); HRMS (EI): MH^+ , found 213.1033. $\text{C}_{13}\text{H}_{13}\text{N}_2\text{O}$ requires
251 213.1028.

252 **2-((1H-benzimidazol-1-yl)ethyl)cyclopent-2-enone 7d**

253 Yield: 85%; yellow oil; ^1H NMR (CDCl_3 , 500 MHz): δ_{H} 8.01 (s, 1H), 7.72–7.69
254 (m, 1H), 7.25–7.12 (m, 4H), 5.25 (q, $J = 6.0$ Hz, 1H), 2.46–2.42 (m, 2H), 2.31–
255 2.30 (m, 2H), 1.74 (d, $J = 6.0$ Hz, 3H) ; ^{13}C NMR (CDCl_3 , 125 MHz): δ_{C} 207.1,
256 159.3, 145.1, 143.4, 141.1, 132.9, 122.7, 122.1, 120.02, 110.2, 47.4, 34.8, 26.2,
257 18.6; MS (m/z): 227 (16), 226 (M^+ , 100), 225 (8), 211 (38), 197 (14), 183 (13), 169

258 (4), 156 (1), 119 (12), 118 (74), 109 (8), 91 (9), 79 (14), 77 (7), 63 (5), 53 (7);
259 HRMS (EI): MH^+ , found 227.1190. $C_{14}H_{15}N_2O$ requires 227.1184.

260 **Typical procedure for the preparation of imidazole derivatives 8**

261 A mixture of acyclic MBH alcohol **1** (1 mmol), imidazole **2a** (2 mmol) and
262 DABCO (1 mmol), was stirred at reflux of methanol or toluene. After completion
263 of the reaction, the solvent was removed by a rotary evaporation and CH_2Cl_2 (10
264 mL) was added. The reaction mixture was washed with brine and dried. Finally, the
265 solvent was removed and the residue was purified by a column chromatography on
266 silica gel, using acetone/ether as eluent, to give the pure imidazole derivative **8**.

267 **Ethyl 2-((1H-imidazol-1-yl)methyl)-3-hydroxypropanoate 8a**

268 Yield: 84%; yellow oil; ν ($CHCl_3$) 3118, 2982, 2934, 1723, 1509, 1451, 1376,
269 1282, 1225, 1181, 1071 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz): δ_H 7.52 (s, 1H), 6.99 (s,
270 1H), 6.95 (s, 1H), 4.77 (s, 1H, OH), 4.35 (d, $J = 6.6$ Hz, 2H), 4.14 (q, $J = 7.1$ Hz,
271 2H), 3.81–3.73 (m, 2H), 2.97–2.91 (m, 1H), 1.22 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR
272 ($CDCl_3$, 75 MHz): δ_C 171.8, 137.8, 128.7, 119.6, 61.2, 59.3, 49.2, 44.6, 14.0;
273 HRMS (EI): MH^+ , found 199.1085. $C_9H_{15}N_2O_3$ requires 199.1083.

274 **Ethyl 2-((1H-imidazol-1-yl)methyl)-3-hydroxy-3-phenylpropanoate 8b**

275 Overall yield: 75%; yellow oil; dr = 55:45. Major diastereomer 1H NMR ($CDCl_3$,
276 300 MHz): δ_H 7.41–7.22 (m, 6H), 6.83–6.76 (m, 2H), 4.85 (d, $J = 6.7$ Hz, 1H),
277 4.46–3.81 (m, 4H), 3.19–3.12 (m, 1H), 1.06 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR ($CDCl_3$,
278 75 MHz): δ_C 172.0, 141.1, 137.3, 129.0, 128.2, 128.2, 126.1, 119.1, 72.6, 61.2,
279 55.0, 45.6, 13.9. Minor diastereomer 1H NMR ($CDCl_3$, 300 MHz): δ_H 7.41–7.22
280 (m, 6H), 6.83–6.76 (m, 2H), 4.92 (d, $J = 7.3$ Hz, 1H), 4.46–3.81 (m, 4H), 3.07–3.01
281 (m, 1H), 0.91 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 75 MHz): δ_C 171.8, 141.7,
282 137.4, 129.0, 128.4, 128.0, 126.3, 119.3, 72.6, 61..., 55.8, 45.3, 13.7; HRMS (EI):
283 MH^+ , found 275.1402. $C_{15}H_{19}N_2O_3$ requires 275.1396.

284 **Methyl 2-((1H-imidazol-1-yl)methyl)-3-hydroxybutanoate 8c**

285 Overall yield: 70%; yellow oil; dr = 59:41. Major diastereomer 1H NMR ($CDCl_3$,
286 300 MHz): δ_H δ_H 7.46 (s, 1H), 6.98 (s, 1H), 6.89 (s, 1H), 5.17 (s, 1H, OH), 4.43–

287 4.30 (m, 2H), 4.05–3.99 (m, 1H), 3.62 (s, 3H), 2.84–2.77 (m, 1H), 1.27 (d, $J = 6.2$
288 Hz, 3H); ^{13}C NMR (CDCl_3 , 75 MHz): δ_{C} 172.8, 137.4, 128.8, 119.4, 66.1, 55.5,
289 52.0, 45.9, 21.9. Minor diastereomer ^1H NMR (CDCl_3 , 300 MHz): δ_{H} 7.49 (s, 1H),
290 6.99 (s, 1H), 6.93 (s, 1H), 5.17 (s, 1H, OH), 4.43–4.30 (m, 2H), 4.05–3.99 (m, 1H),
291 3.67 (s, 3H), 2.92–2.87 (m, 1H), 1.25 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (CDCl_3 , 75
292 MHz): δ_{C} 172.3, 137.5, 128.9, 119.4, 65.8, 54.3, 52.0, 45.0, 20.7; HRMS (EI):
293 MH^+ , found 199.1085. $\text{C}_9\text{H}_{15}\text{N}_2\text{O}_3$ requires 199.1083.

294 **3-Hydroxy-2-((1H-imidazol-1-yl)methyl)-1-phenylpropan-1-one 8d**

295 Yield: 70%; ^1H NMR (CDCl_3 , 300 MHz): δ_{H} 7.85–7.82 (m, 2H), 7.56–7.36 (m,
296 4H), 6.90 (s, 1H), 6.87 (s, 1H), 6.41 (s, 1H, OH), 4.52–4.34 (m, 2H), 4.02–3.94 (m,
297 1H), 3.88–3.70 (m, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ_{C} 199.8, 137.6, 136.1,
298 133.6, 128.8, 128.7, 128.2, 119.7, 60.7, 51.5, 45.1; HRMS (EI): MH^+ , found
299 231.1132. $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_2$ requires 231.1134.

300 **1-Hydroxy-2-((1H-imidazol-1-yl)methyl)hexan-3-one 8e**

301 Yield: 76%; ^1H NMR (CDCl_3 , 300 MHz): δ_{H} 7.45 (s, 1H), 6.97 (s, 1H), 6.89 (s,
302 1H), 4.63 (s, 1H, OH), 4.36–4.17 (m, 2H), 3.80–3.69 (m, 2H), 3.11–3.05 (m, 1H),
303 2.56–2.26 (m, 2H), 1.56–1.49 (m, 2H), 0.84 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (CDCl_3 ,
304 75 MHz): δ_{C} 210.6, 137.7, 128.9, 119.5, 59.8, 55.7, 44.9, 44.5, 16.7, 13.5; HRMS
305 (EI): MH^+ , found 197.1293. $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_2$ requires 197.1290.

306 **1-Cyclohexyl-3-hydroxy-2-((1H-imidazol-1-yl)methyl)propan-1-one 8f**

307 Yield: 73%; ^1H NMR (CDCl_3 , 300 MHz): δ_{H} 7.43 (s, 1H), 6.96 (s, 1H), 6.88 (s,
308 1H), 4.71 (s, 1H, OH), 4.36–4.16 (m, 2H), 3.74–3.41 (m, 2H), 3.31–3.24 (m, 1H),
309 2.42–2.34 (m, 1H), 1.72–1.54 (m, 5H), 1.43–1.15 (m, 5H); ^{13}C NMR (CDCl_3 , 75
310 MHz): δ_{C} 213.6, 137.6, 128.8, 119.5, 60.3, 54.4, 50.8, 45.0, 29.6, 28.0, 27.2, 25.7,
311 25.2; HRMS (EI): MH^+ , found 237.1607. $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_2$ requires 237.1603.

312 ■ ASSOCIATED CONTENT

313 Supporting Information

314 The Supporting Information is available free of charge at


315

316 ¹H and ¹³C NMR and HRMS spectra of compounds (PDF)

317


318 ■ AUTHOR INFORMATION

319 Corresponding Author

320 **Olfa MHASNI** – Laboratory of Materials, Treatment and Analysis LMTA, LR 15
321 INRAP 03, Institute National for Research and Physico-Chemical Analysis
322 (INRAP), Biotechpole Sidi Thabet 2020, Tunisia;  [orcid.org/0009-0002-9931-](https://orcid.org/0009-0002-9931-0895)
323 [0895](https://orcid.org/0009-0002-9931-0895); *Email : olfa.mha@gmail.com

324 Authors

325 **Jalloul BOUAJILA** – Paul Sabatier University, Toulouse 3, Laboratoire de Génie
326 Chimique UMR 5503 Toulouse France; E-mail : jalloul.bouajila@univ-tlse3.fr

327 **Farhat REZGUI** – University of Tunis El Manar, Laboratory of Organic
328 Chemistry, Faculty of Sciences, Campus, 2092 Tunis, Tunisia;  [orcid.org/0000-](https://orcid.org/0000-0002-9616-0716)
329 [0002-9616-0716](https://orcid.org/0000-0002-9616-0716); E-mail : farhat.rezgui@fst.utm.tn

330 Notes

331 The authors declare no competing financial interest.

332 ■ ACKNOWLEDGMENTS

333 We are grateful to the DGRST, Ministry of Higher Education, Tunisia, for the
334 financial support of this work.

335 ■ References

- 336 **1.** (a) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Recent Advances in the
337 Baylis–Hillman Reaction and Applications. *Chem. Rev.* **2003**, *103*, 811.
338 (b) Basavaiah, D.; Reddy, B. S.; Badsara, S. S. Recent Contributions from
339 the Baylis–Hillman Reaction to Organic Chemistry. *Chem. Rev.* **2010**, *110*,

- 340 5447. (c) Declerck, V.; Martinez, J.; Lamaty, F. *aza*-Baylis–Hillman
341 Reaction. *Chem. Rev.* **2009**, *109*, 1.
- 342 **2.** (a) Zhang, X. X.; Rao, W. D.; Chan, S. W. H.; Chan, P. W. H. Iron(III)
343 Chloride-Catalysed Direct Nucleophilic α -Substitution of Morita–Baylis–Hillman
344 Alcohols with Alcohols, Arenes, 1,3-Dicarbonyl Compounds, and Thiols. *Org.*
345 *Biomol. Chem.* **2009**, *7*, 4186. (b) Kim, H. S.; Gowrisankar, S.; Kim, S. H.;
346 Kim, J. N. Synthesis of 6-Oxacyclopropa[*a*]indene Derivatives Starting from
347 Baylis–Hillman Adducts via Pd-mediated C(sp³)–H Activation. *Tetrahedron*
348 *Lett.* **2008**, *49*, 3858. (c) Kamimura, A.; Morita, R.; Matsuura, K.; Omata, Y.;
349 Shirai, M. Simple Preparation of β -Hydroxy- α -thiomethyl Carbonyl
350 Compounds via Stereoselective Conjugate Addition of Thiol to Baylis–
351 Hillman Adducts. *Tetrahedron Lett.* **2002**, *43*, 6189. (d) Lee, C. G.; Lee, K.
352 Y.; Lee, S.; Kim, J. N. Chemical Transformation of Baylis–Hillman Adducts:
353 the Reaction of Methyl 3-Arylamino-2-methylene-3-phenylpropanoates in
354 Polyphosphoric Acid. *Tetrahedron* **2005**, *61*, 1493.
- 355 **3.** Gilchrist, T. L. *Heterocyclic Chemistry*, 3rd ed.; Logman: Singapore, **1997**,
356 Chapter 8.
- 357 **4.** (a) Botta, M.; Corelli, F.; Gasparri, F.; Messina, F.; Mugnaini, C. Chiral
358 Azole Derivatives. 4. Enantiomers of Bifonazole and Related Antifungal
359 Agents: Synthesis, Configuration Assignment, and Biological Evaluation. *J.*
360 *Org. Chem.* **2000**, *65*, 4736. (b) Corelli, F.; Summa, V.; Brogi, A.;
361 Monteagudo, E.; Botta, M. Chiral Azole Derivatives. 2. Synthesis of
362 Enantiomerically Pure 1-Alkylimidazole. *J. Org. Chem.* **1995**, *60*, 2008.
- 363 **5.** For reviews on direct substitutions of π -alcohols, see: Mhasni, O.; Elleuch, H.;
364 Rezgui, F. Direct Nucleophilic Substitutions of Allylic Alcohols with
365 1,3-Dicarbonyl Compounds: Synthetic Design, Mechanistic Aspects and
366 Applications. *Tetrahedron* **2022**, *111*, 132732.
- 367 **6.** (a) Jana, U.; Maiti, S.; Biswas, S. An Efficient FeCl₃-Catalyzed Amidation
368 Reaction of Secondary Benzylic and Allylic Alcohols with Carboxamides or
369 *p*-Toluenesulfonamide. *Tetrahedron Lett.* **2008**, *49*, 858. (b) Lee, K. Y.; Lee,

- 370 H. S.; Kim, J. N. Facile Synthesis of *Aza*-Baylis–Hillman Adducts of
371 Cycloalkenones: FeCl₃-Mediated Direct Amination of Baylis–Hillman
372 Alcohols. *Bull. Korean Chem. Soc.* **2008**, *29*, 1099.
- 373 **7.** Liu, Y-L.; Liu, L.; Wang, D.; Chen, Y-J. A Highly α -Regioselective
374 In(OTf)₃-Catalyzed *N*-Nucleophilic Substitution of Cyclic Baylis–Hillman
375 Adducts with Aromatic Amines. *Tetrahedron* **2009**, *65*, 3473.
- 376 **8.** Reddy, C. R.; Madhavi, P. P.; Reddy, A. S. Molybdenum(V) Chloride-
377 Catalyzed Amidation of Secondary Benzyl Alcohols with Sulfonamides and
378 Carbamates. *Tetrahedron Lett.* **2007**, *48*, 7169.
- 379 **9.** Guo, S.; Song, F.; Liu, Y. Gold-Catalyzed Direct Amination of Allylic
380 Alcohols. *Synlett* **2007**, 964.
- 381 **10.** Wu, W.; Rao, W.; Er, Y. Q.; Loh, J. K.; Poh, C. Y.; Chan, P. W. H. Iodine-
382 Catalyzed Allylic Alkylation of Sulfonamides and Carbamates with Allylic
383 Alcohols at room Temperature. *Tetrahedron Lett.* **2008**, *49*, 2620.
- 384 **11.** (a) Yang, S.-C.; Chung, W.-H. Palladium-Catalyzed *N*-Allylation of Anilines
385 by Direct Use of Allylic Alcohols in the Presence of Titanium(IV)
386 Isopropoxide. *Tetrahedron Lett.* **1999**, *40*, 953. (b) Yang, S.-C.; Hsu, Y.-C.;
387 Gan, K.-H. Direct Palladium/Carboxylic Acid-Catalyzed Allylation
388 of Anilines with Allylic Alcohols in Water. *Tetrahedron* **2006**, *62*, 3949.
- 389 **12.** Dongyan, Y. E.; Jian, L. I.; Chunju, L. I.; Xueshun, J. I. A. Facile Syntheses
390 of *N*-Substituted Imidazoles and Benzotriazoles from Baylis–Hillman
391 Bromides. *Chin. J. Chem.* **2009**, *27*, 1159.
- 392 **13.** Li, J.; Wang, X.; Zhang, Y. Remarkable Rate Acceleration of Water-
393 Promoted Nucleophilic Substitution of Baylis–Hillman Acetate: a Facile
394 and Highly Efficient Synthesis of *N*-Substituted Imidazole. *Tetrahedron Lett.*
395 **2005**, *46*, 5233.
- 396 **14.** Rodrigues Jr, M. T.; Santos, M.S.; Santos, H.; Coelho, F.
397 1,1'-Carbonyldiimidazole Mediates the Synthesis of *N*-Substituted

- 398 Imidazole Derivatives from Morita–Baylis–Hillman Adducts. *Tetrahedron*
399 *Lett.* **2014**, *55*, 180.
- 400 **15.** Oueslati, Y.; Baioui, N.; Rezgui, F. A Transition Metal-Free Direct
401 Nucleophilic α -substitution of Morita–Baylis–Hillman Alcohols with
402 Amines and Thiols. *Synth. Commun.* **2017**, *47*, 892.
- 403 **16.** Mhasni, O.; Rezgui, F. The First DMAP-Mediated Palladium-Free Tsuji–
404 Trost-type Reaction of Cyclic and Acyclic Baylis–Hillman Alcohols with
405 Active Methylene Compounds. *Tetrahedron Lett.* **2010**, *51*, 586.
- 406 **17.** Elleuch, H.; Ayadi, M.; Bouajila, J.; Rezgui, F. Synthesis of a Series of
407 γ -Keto Allyl Phosphonates. *J. Org. Chem.* **2016**, *81* (5), 1757.
- 408 **18.** Ayadi, M.; Elleuch, H.; Vrancken, E.; Rezgui, F. First DMAP-Mediated
409 Direct Conversion of Morita–Baylis–Hillman Alcohols into
410 γ -Ketoallylphosphonates: Synthesis of γ -Aminoallylphosphonates. *Beilstein*
411 *J. Org. Chem.* **2016**, *12*, 2906.
- 412 **19.** K. Harrath, K. Essalah, C. Morell, H. Chermette, S. Boughdiri. Alkylation of
413 Active Methylene Compounds with Cyclic Baylis–Hillman Alcohols: a DFT
414 Study. *Theor. Chem. Acc.* **2015**, *134* (98), 1.
- 415 **20.** Smith, A.B, III.; Wexler, B. A.; Slade, J. S. Bis- β,β' -Conjugate Addition.
416 *Tetrahedron Lett.* **1980**, *21*, 3237.
- 417 **21.** Tamura, R.; Tamai, S.; Katayama, H.; Suzuki, H. Me_3SiCl Promoted
418 Conjugate Addition of Organocuprates to Base-Sensitive Cyclic α -
419 (Nitroalkyl). *Tetrahedron Lett.* **1989**, *30*, 3685.
- 420 **22.** Chung, Y.M.; Gong, J. H.; Kim, T. H.; Kim, J. N. Synthesis of Ethyl
421 3-cyano-2-methylcinnamates and 3-Cyano-2-methylcinnamionitriles from the
422 Baylis–Hillman Acetates. *Tetrahedron Lett.* **2001**, *42*, 9023.
- 423 **23.** Lee, C. G.; Gowrisankar, S.; Kim, J. N. Synthesis of Substituted Uracil
424 Derivatives from the Acetates of the Baylis–Hillman Adducts. *Bull. Korean*
425 *Chem. Soc.* **2005**, *26*, (3), 481.
- 426 **24.** Ge, S.-Q.; Hua, Y.-Y.; Xia, M. Ultrasound-promoted access to Baylis–
427 Hillman amines. *Ultrason. Sonochem.* **2009**, *16*, 743.

- 428 **25.** Baidya, M.; Brotzel, F.; Mayr, H. Nucleophilicities and Lewis Basicities of
429 Imidazoles, Benzimidazoles, and Benzotriazoles. *Org. Biomol. Chem.* **2010**,
430 8, 1929.
- 431 **26.** (a) Amri, H.; El Gaied, M.M.; Ben Ayed, T.; Villieras, J. Nouvelle Synthèse
432 d' α -(1-hydroxy)alkyl- β -lactames. *Tetrahedron Lett.* **1992**, 33, 6159.
433 (b) Ben Ayed, T.; Amri, H.; El Gaied, M.M.; Villieras, J. Addition Conjugué
434 d'Amines Primaires aux Composés Acryliques α -(1-hydroxyalkylés):
435 Nouvelles Synthèses de β - et de γ -Lactames Polyfonctionnels. *Tetrahedron*
436 **1995**, 51, 9633.
- 437 **27.** (a) Kobayashi, Y.; Kiyotsuka, Y.; Sugihara, Y.; Wada, K. Installation of the
438 Imidazole Ring on Chiral Substrates via Allylic Substitution. *Tetrahedron*
439 **2015**, 71, 6481. (b) Bellina, F.; Lessia, M.; Marianetti, G.; Panattoni, A.
440 Highly Regioselective C-5 Alkynylation of Imidazoles by One-pot Sequential
441 Bromination and Sonogashira Cross Coupling. *Tetrahedron Lett.* **2015**, 56,
442 3855.
- 443 **28.** (a) Devi, N.; Rawal, R. K.; Singh, V. Diversity-Oriented Synthesis of Fused-
444 Imidazole Derivatives via Groebke–Blackburn–Bienayme Reaction:
445 a Review. *Tetrahedron* **2015**, 71, 183. (b) Bellina, F.; Guazzelli, N.; Lessi,
446 M.; Manzini, C. Imidazole Analogues of Resveratrol: Synthesis and Cancer
447 Cell Growth Evaluation. *Tetrahedron* **2015**, 71, 2298. (c) Aruchamy,
448 B.; Drago, C.; Russo, V.; Pitari, G. M.; Ramani, P.; Aneesh, T. P.; Benny,
449 S.; Vishnu, V. R. Imidazole-Pyridine Hybrids as Potent Anti-Cancer Agents.
450 *Eur. J. Pharm. Sci.* **2023**, 180, 106323.